



## Update Summary

---

**Entity name**

KAZIA THERAPEUTICS LIMITED

**Announcement Type**

Update to previous announcement

**Date of this announcement**

Friday October 2, 2020

**Reason for update to a previous announcement**

Certain aspects of the transaction are now finalised, including the underwriting agreement, the top up facility and the scale back provisions.

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of +Entity**

KAZIA THERAPEUTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

**1.2 Registered Number Type**

ABN

**Registration Number**

37063259754

**1.3 ASX issuer code**

KZA

**1.4 The announcement is**

Update/amendment to previous announcement

**1.4a Reason for update to a previous announcement**

Certain aspects of the transaction are now finalised, including the underwriting agreement, the top up facility and the scale back provisions.

**1.4b Date of previous announcement(s) to this update**

Thursday October 1, 2020

**1.5 Date of this announcement**

Friday October 2, 2020

**1.6 The Proposed issue is:**

An accelerated offer

**1.6b The proposed accelerated offer is**

Accelerated non-renounceable entitlement offer (commonly known as a JUMBO or ANREO)



Part 3 - Details of proposed entitlement offer issue

---

Part 3A - Conditions

---

**3A.1 - Are any of the following approvals required for the entitlement offer to be unconditional?**

- **+Security holder approval**
- **Court approval**
- **Lodgement of court order with +ASIC**
- **ACCC approval**
- **FIRB approval**
- **Another approval/condition external to the entity**

No

Part 3B - Offer details

---

**Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued**

**ASX +security code and description**

KZA : ORDINARY FULLY PAID

**Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?**

Existing class

**Will the proposed issue of this +security include an offer of attaching +securities?**

No

**If the entity has quoted company options, do the terms entitle option holders to participate on exercise?**

No

Details of +securities proposed to be issued

---

**ASX +security code and description**

KZA : ORDINARY FULLY PAID

**ISIN Code (if Issuer is a foreign company and +securities are non CDIs)**

**ISIN Code for the entitlement or right to participate in the offer (if Issuer is foreign company and +securities are non CDIs)**

**Offer ratio (ratio to existing holdings at which the proposed +securities will be issued)**

**Has the offer ratio been determined?**

Yes



<b>The quantity of additional +securities to be issued</b>	<b>For a given quantity of +securities held</b>
--	---

1

3

**What will be done with fractional entitlements?**

Fractions rounded up to the next whole number

**Maximum number of +securities proposed to be issued (subject to rounding)**

31,541,123

**Reason for the update of 'Maximum Number of +securities proposed to be issued'****Offer price details for retail security holders****Has the offer price for the retail offer been determined?** Yes**In what currency will the offer be made?**

AUD - Australian Dollar

**What is the offer price per +security for the retail offer?**

AUD 0.80000

**Offer price details for institutional security holders****Has the offer price for the institutional offer been determined?** Yes**In what currency will the offer be made?**

AUD - Australian Dollar

**What is the offer price per +security for the institutional offer?**

AUD 0.80000

**Oversubscription & Scale back details****Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)?** Yes**Describe the limits on over-subscription**

Eligible retail shareholders may apply for Kazia ordinary shares (New Shares) in excess of their entitlement up to a maximum of 100% of their entitlement (Additional New Shares). Any Additional New Shares will be limited to the extent that there are sufficient New Shares from eligible retail shareholders who do not take up their full entitlements.

**Will a scale back be applied if the offer is over-subscribed?** Yes**Describe the scale back arrangements**

If there are excess oversubscription applications, Kazia reserves the right to scale back applications for Additional New Shares in its absolute discretion. In the event of a scale-back, the difference between application monies received and the number of Additional New Shares allocated to an eligible retail shareholder multiplied by the offer price will be refunded. No interest will be paid in any application monies which are received and refunded.



**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

---

## Part 3D - Timetable

---

### **3D.1a First day of trading halt**

Wednesday September 30, 2020

### **3D.1b Announcement date of accelerated offer**

Thursday October 1, 2020

### **3D.2 Trading resumes on an ex-entitlement basis (ex date)**

Friday October 2, 2020

### **3D.5 Date offer will be made to eligible institutional +security holders**

Thursday October 1, 2020

### **3D.6 Application closing date for institutional +security holders**

Thursday October 1, 2020

### **3D.8 Announcement of results of institutional offer**

**(The announcement should be made before the resumption of trading following the trading halt)**

Friday October 2, 2020

### **3D.9 +Record date**

Monday October 5, 2020

### **3D.10a Settlement date of new +securities issued under institutional entitlement offer**

Friday October 9, 2020

### **3D.10b +Issue date for institutional +security holders**

Friday October 9, 2020

### **3D.10c Normal trading of new +securities issued under institutional entitlement offer**

Monday October 12, 2020

### **3D.11 Date on which offer documents will be sent to retail +security holders entitled to participate in the +pro rata issue**

Thursday October 8, 2020

### **3D.12 Offer closing date for retail +security holders**

Tuesday October 20, 2020



**3D.13 Last day to extend retail offer close date**

Thursday October 15, 2020

**3D.16 Entity announces results of retail offer, including the number and percentage of +securities taken up by existing retail +security holders.**

Friday October 23, 2020

**3D.19 +Issue date for retail +security holders**

Tuesday October 27, 2020

Part 3E - Fees and expenses

---

**3E.1 Will there be a lead manager or broker to the proposed offer?**

Yes

**3E.1a Who is the lead manager/broker?**

Bell Potter Securities Limited

**3E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?**

3% of offer proceeds

**3E.2 Is the proposed offer to be underwritten?**

Yes

**3E.2a Who are the underwriter(s)?**

Bell Potter Securities Limited

**3E.2b What is the extent of the underwriting (ie the amount or proportion of the offer that is underwritten)?**

Fully underwritten

**3E.2c What fees, commissions or other consideration are payable to them for acting as underwriter(s)?**

3% of offer proceeds, other than proceeds received from entitlements of directors and other selected shareholders

**3E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated**

See summary in announcement dated 2 October 2020

**3E.2e Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed offer?**

No

**3E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?**

No



**3E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer**

Standard share registry, external advisors and ASX administrative fees

Part 3F - Further Information

**3F.1 The purpose(s) for which the entity intends to use the cash raised by the proposed issue**

To fund Kazia's participation in the GBM Agile study for paxalisib in glioblastoma, as well as for general working capital

**3F.2 Will holdings on different registers or subregisters be aggregated for the purposes of determining entitlements to the issue?**

No

**3F.3 Will the entity be changing its dividend/distribution policy if the proposed issue is successful?**

No

**3F.4 Countries in which the entity has +security holders who will not be eligible to participate in the proposed issue**

Institutional Entitlement Offer: all jurisdictions other than Australia, New Zealand, United Kingdom, Singapore, Hong Kong and the United States.

Retail Entitlement Offer: all jurisdictions other than Australia and New Zealand

**3F.5 Will the offer be made to eligible beneficiaries on whose behalf eligible nominees or custodians hold existing +securities**

Yes

**3F.5a Please provide further details of the offer to eligible beneficiaries**

The Retail Entitlement Offer will be made available to nominees with a registered address in Australia or New Zealand who were registered as a holder of Kazia Shares at 7.00pm (Sydney time) on Monday 5 October 2020 and who held those Shares on behalf of underlying beneficial holders (wherever they reside), except to the extent that those underlying beneficial holders are not an eligible retail shareholder. The Retail Entitlement Offer is not available to shareholders that are in the United States or who are, or are acting for the account or benefit of, persons in the United States.

**3F.6 URL on the entity's website where investors can download information about the proposed issue**

<https://www.kaziatherapeutics.com/home>

**3F.7 Any other information the entity wishes to provide about the proposed issue**

N/A

**3F.8 Will the offer of rights under the rights issue be made under a disclosure document or product disclosure statement under Chapter 6D or Part 7.9 of the Corporations Act (as applicable)?**

No